BTI.V - Bioasis Technologies Inc.

TSXV - TSXV Delayed Price. Currency in CAD
0.2300
-0.0200 (-8.00%)
At close: 2:54PM EST
Stock chart is not supported by your current browser
Previous Close0.2500
Open0.2250
Bid0.2250 x 0
Ask0.2300 x 0
Day's Range0.2250 - 0.2300
52 Week Range0.1800 - 0.4600
Volume86,900
Avg. Volume33,954
Market Cap14.607M
Beta (5Y Monthly)0.25
PE Ratio (TTM)N/A
EPS (TTM)-0.0700
Earnings DateJan 28, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.00
  • Growth Company Investor Presentations Now Available for On-Demand Viewing
    PR Newswire

    Growth Company Investor Presentations Now Available for On-Demand Viewing

    Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the February 20th conference are now available for on-demand viewing at VirtualInvestorConferences.com.

  • PR Newswire

    Bioasis to Present at the OTC Markets 2020 Virtual Investor Conference

    Bioasis Technologies Inc. (OTCQB:BIOAF; TSX.V:BTI), (the "Company" or "Bioasis"), a biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier ("BBB") and the treatment of central nervous system ("CNS") disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that Dr. Deborah Rathjen, Executive Chair and Chief Executive Officer of Bioasis will present at the OTC Virtual Investor Conference.

  • CNW Group

    Live Investor Conference & Webinar: Growth Company CEOs Present February 20th

    Live Investor Conference & Webinar: Growth Company CEOs Present February 20th

  • Business Wire

    Bioasis to Present at the 22nd Annual BIO CEO Investor Conference and the OTC Markets 2020 Virtual Investor Conference

    Bioasis Technologies Inc. (OTCQB:BIOAF)(TSX.V:BTI), (the "Company" or "Bioasis"), a biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier ("BBB") and the treatment of central nervous system ("CNS") disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that Dr. Deborah Rathjen, Executive Chair and Chief Executive Officer of Bioasis will present at the following conferences:

  • Business Wire

    Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending November 30, 2019

    Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the "Company" or "Bioasis"), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier ("BBB") and the treatment of central nervous system ("CNS") disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced it has filed its unaudited quarterly financial statements and management’s discussion and analysis for the period ended November 30, 2019. All are available under the Company’s profile on SEDAR at www.sedar.com and on the Company’s website at www.bioasis.us/investors/.

  • Business Wire

    Bioasis Technologies Inc. Announces Warrant Extension and Repricing

    Bioasis Technologies Inc. ("Bioasis" or the "Company") (OTCQB:BIOAF; TSX.V:BTI), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the blood-brain barrier ("BBB") and the treatment of central nervous system ("CNS") disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that it has applied for approval from the TSX Venture Exchange to extend the expiry date of 4,588,978 common share purchase warrants issued to subscribers pursuant to the private placement of units which closed on May 21, 2019 and to amend the exercise price of the warrants. Bioasis intends to extend the expiry date of the warrants from May 21, 2023 until May 21, 2024 and to reduce the exercise price from $0.60 to $0.36.

  • Business Wire

    Bioasis Announces Shares for Debt Transaction

    BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI), (the "Company" or "Bioasis"), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier ("BBB") and the treatment of central nervous system ("CNS") disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that it has satisfied its obligation to pay $16,352.28 in interest to the holders of its 15% unsecured debentures issued November 8, 2019 (the "Debentures") on December 31, 2019 by issuing 65,403 common shares of the company. The common shares were issued at a deemed price of $0.25 per share in full satisfaction of the December 31 interest payment obligation in accordance with the terms of the Debentures. The Company chose to settle the interest through the issuance of common shares in order to preserve the amount of cash available to fund ongoing operations while it continues to pursue additional financing opportunities, including potential partnerships.

  • Business Wire

    Bioasis to Present at Upcoming Industry Conferences

    BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI), (the "Company" or "Bioasis"), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier ("BBB") and the treatment of central nervous system ("CNS") disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that Dr. Deborah Rathjen, Executive Chair and Chief Executive Officer of Bioasis will present at the following industry conferences:

  • Investors Who Bought Bioasis Technologies (CVE:BTI) Shares Three Years Ago Are Now Down 83%
    Simply Wall St.

    Investors Who Bought Bioasis Technologies (CVE:BTI) Shares Three Years Ago Are Now Down 83%

    Every investor on earth makes bad calls sometimes. But really bad investments should be rare. So consider, for a...